The aim of the project is the development and the pre-clinical evaluation of a mucosal RNA-based virosomal vaccine against respiratory diseases of the early childhood caused by human parainfluenzavirus type 3 and respiratory syncytial virus. Antigens are encoded on a Sendai virus RNA packaged in a nucleocapsid and encapsulated into immunostimulating reconstituted virosomes. For an excellent safety standard, the nucleocapsid is completely replication-deficient by deletion of the N gene. Antigen combinations are provided by a single vaccine formulation in a modular system. The vaccine will be applied in a one step process and the administration as a nasal spray allows an easy reapplication. This makes the new formulation economic, effective, safe and highly adaptable for vaccination of humans (also of animals) against various infectious diseases.
Funding SchemeCSC - Cost-sharing contracts
47 Maynooth - Co. Kildare